Linezolid

Restricted
C difficile risk
Low
Oral Bioavailability
N/A

Spectrum Of Activity

Dosing

Children < 5 years of age: 30 mg/kg/DAY IV divided q8h Children 5 to 11 years of age: 20-30 mg/kg/DOSE IV divided q8h-q12hChildren ≥12 years and adolescents: 20 mg/kg/DAY IV divided q12h; maximum 600 mg/DOSE

PNA <7 days and <1200 g: 20 mg/kg/DAY IV divided q12hPNA <7 days and ≥1200 g: 20-30 mg/kg/DAY IV divided q8-12hPNA ≥7 days and <1200 g: 20-30 mg/kg/DAY IV divided q8-12hPNA ≥7 days and ≥1200 g: 30 mg/kg/DAY IV divided q8h

No dosage adjustment recommended in hepatic insufficiency. Use in severe hepatic impairment has not been adequately evaluated.

No dosage adjustment necessary in renal insufficiency, however inactive metabolites may accumulate in renal insufficiency.

General Information

  • Targeted or empiric therapy for gram positive infections including skin and soft tissue, and pneumonia.

  • Covers MRSA and VRE

  • CBC at least once/week.

  • Visual testing for therapy >3mo or if symptoms develop on therapy.

  • Myelosuppression (usually with >2weeks therapy) - reversible

  • Peripheral/optic neuropathy with prolonged courses

  • Rash

  • Elevated liver enzymes

  • Lactic acidosis

SSRI and other serotonergics/MAOIs - increased risk of serotonin syndrome

Rifampin decreases linezolid levels.

Antimicrobial class: Oxazolidinone

Average serum half life:

  • Preterm neonates <1 week: 5.6 hours

  • Full-term neonates < 1 week : 3 hours

  • Full-term neonates ≥1 week to ≤ 28 days: 1.5 hours

  • Infants > 28 days to < 3 months: 1.8 hours

  • Infants and Children 3 months to 11 years: 2.9 hours

  • Adolescents: 4.1 hours

  • Adults: 4.9 hours

Route of Elimination:

  • Urine (~30% of total dose as parent drug, ~50 of total dose as inactive metabolites), two metabolites may accumulate in patients with severe renal impairment

  • Feces (9% of total dose as metabolites)